4.7 Review

Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 30, Issue 34, Pages 4249-4255

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2012.42.5967

Keywords

-

Categories

Funding

  1. Pfizer
  2. Helsinn Therapeutics
  3. Amgen
  4. KangLaiTe USA
  5. Alexion
  6. BioVex
  7. DARA BioSciences
  8. Mi-Co
  9. Eli Lilly
  10. Endo Pharmaceuticals
  11. Bristol-Myers Squibb
  12. Genentech
  13. Bayer Pharmaceuticals

Ask authors/readers for more resources

Examining the patient's subjective experience in prospective clinical comparative effectiveness research (CER) of oncology treatments or process interventions is essential for informing decision making. Patient-reported outcome (PRO) measures are the standard tools for directly eliciting the patient experience. There are currently no widely accepted standards for developing or implementing PRO measures in CER. Recommendations for the design and implementation of PRO measures in CER were developed via a standardized process including multistakeholder interviews, a technical working group, and public comments. Key recommendations are to include assessment of patient-reported symptoms as well as health-related quality of life in all prospective clinical CER studies in adult oncology; to identify symptoms relevant to a particular study population and context based on literature review and/or qualitative and quantitative methods; to assure that PRO measures used are valid, reliable, and sensitive in a comparable population (measures particularly recommended include EORTC QLQ-C30, FACT, MDASI, PRO-CTCAE, and PROMIS); to collect PRO data electronically whenever possible; to employ methods that minimize missing patient reports and include a plan for analyzing and reporting missing PRO data; to report the proportion of responders and cumulative distribution of responses in addition to mean changes in scores; and to publish results of PRO analyses simultaneously with other clinical outcomes. Twelve core symptoms are recommended for consideration in studies in advanced or metastatic cancers. Adherence to methodologic standards for the selection, implementation, and analysis/reporting of PRO measures will lead to an understanding of the patient experience that informs better decisions by patients, providers, regulators, and payers. J Clin Oncol 30:4249-4255. (C) 2012 by American Society of Clinical Oncology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available